Compare BWB & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | BWB | ENGN |
|---|---|---|
| Founded | 2005 | 1999 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 515.6M | 605.5M |
| IPO Year | 2018 | N/A |
| Metric | BWB | ENGN |
|---|---|---|
| Price | $17.49 | $9.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | $20.33 | ★ $22.71 |
| AVG Volume (30 Days) | 87.6K | ★ 245.0K |
| Earning Date | 01-28-2026 | 12-22-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.72 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | ★ $127,243,000.00 | N/A |
| Revenue This Year | $35.67 | N/A |
| Revenue Next Year | $14.88 | N/A |
| P/E Ratio | $13.28 | ★ N/A |
| Revenue Growth | ★ 20.40 | N/A |
| 52 Week Low | $11.93 | $2.65 |
| 52 Week High | $19.11 | $11.14 |
| Indicator | BWB | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 41.95 | 58.22 |
| Support Level | $17.90 | $7.57 |
| Resistance Level | $19.11 | $9.81 |
| Average True Range (ATR) | 0.38 | 0.72 |
| MACD | -0.15 | 0.04 |
| Stochastic Oscillator | 2.39 | 60.47 |
Bridgewater Bancshares Inc is a financial holding company. Through its subsidiary, it offers various personal and commercial banking products and services such as savings accounts, certificates of deposits, money transfer services, digital wallets, credit and debit cards, safe deposit lockers, different types of loans and advances, commercial deposit accounts, treasury management, and others. The company principally focuses on catering to commercial clients, offering them a suite of loan and deposit products. Geographically, it mainly operates in the Twin Cities Metropolitan Statistical Area in the United States.
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.